ArticleEuropean journal of immunology2025
Activation of CD8⁺ T Cells in the Human Ex Vivo Lung Tumor Microenvironment Using Anti-CD3/CD28 and Nivolumab.
Article in European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tumor-associated macrophages in head and neck carcinoma: clinicopathological correlations and implications for immunotherapy.Cancer immunology, immunotherapy : CII · 2026Article
- Regulation of T cell tissue residency and activation in human PCLS.Respiratory research · 2025Article
- Activation of CD8⁺ T Cells in the Human Ex Vivo Lung Tumor Microenvironment Using Anti-CD3/CD28 and Nivolumab.European journal of immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advancements in immunotherapies, the diversity of the tumor microenvironment remains a challenge for cancer treatment. To elucidate microenvironment-specific differences in antitumor responses, we established patient-derived ex vivo tumor-lung slices. We analyzed immune activation profiles after treatment with anti-CD3/CD28 and the checkpoint inhibitor Nivolumab. Lung slices from non-tumor, tumor-adjacent, tumor-border, and tumor-central tissue were generated and assessed for viability, cell composition, and immune competence via flow cytometry, soluble factor secretion, and bulk RNA-sequencing. The tumor-border contained the highest number of immune cells (8.3-fold vs. non-tumor), secreted tumor markers (S100 and CA15-3), and exhibited high levels of inflammatory mediators (IFNγ, IL-6, and IL-2). Treatment with anti-CD3/CD28 increased the frequency of CD137
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.